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Gene expressionHuman parvovirus 4 (PARV4) is an emerging human virus, and little is known about the molecular aspects of
PARV4 apart from its incomplete genome sequence, which lacks information of the termini. We analyzed the
gene expression proﬁle of PARV4 using a nearly full-length HPV4 genome in a replication competent system
in 293 cells. We found that PARV4 utilizes two promoters to transcribe non-structural protein- and structural
protein-encoding mRNAs, respectively, which were polyadenylated at the right end of the genome. Three
major proteins, including the large non-structural protein NS1a, whose mRNA is spliced, and capsid proteins
VP1 and VP2, were detected. Additional functional analysis of the NS1a revealed its capability to induce cell
cycle arrest at G2/M phase in ex vivo-generated human hematopoietic stem cells. Taken together, our char-
acterization of the molecular features of PARV4 suggests that PARV4 represents a new genus in the family
Parvoviridae.
© 2011 Elsevier Inc. All rights reserved.Introduction
Parvoviruses are small non-enveloped, icosahedral DNA viruses
with a diameter of 18–26 nm that encapsidate a single-stranded ge-
nome of approximately (~)5–6 kb (Tattersall, 2006). To date, there are
a number of parvoviruses known to infect humans, including adeno-
associated viruses (AAVs), parvovirus B19 (B19V), and two newly iden-
tiﬁed human parvoviruses, which are the human bocavirus (HBoV)
(Allander et al., 2005) and human parvovirus 4 (PARV4) (Jones et al.,
2005). B19V, a prototype member in the genus Erythrovirus of the fam-
ily Parvoviridae, causes a number of human diseases ranging from mild
erythema infectiosum and polyarthropathy syndrome to severe mani-
festations of transient aplastic crisis, pure red cell aplasia and hydrops
fetalis (Young and Brown, 2004). In contrast, AAVs, members of the
genus Dependovirus, are non-pathogenic to humans, and have been
widely used as therapeutic vectors in human gene therapy (Brown,
2010; Mingozzi and High, 2011).
HBoV was ﬁrstly identiﬁed in respiratory samples from children
with lower respiratory tract infections (Allander et al., 2005), and sub-
sequently proven epidemiologically to be associated with the diseases
(Manning et al., 2006). PARV4 was initially found in a blood sampleiseases, First Afﬁliated Hospital,
710061, Shaanxi Province,
u).
rights reserved.from an intravenous drug user with acute viral infection syndrome
(Jones et al., 2005). Subsequently, the PARV4 genome was detected in
human plasma pools at a low titer (Schneider et al., 2008a). PARV4
had also been found in the livers of hepatitis C virus-positive individuals
(Schneider et al., 2008b) and the bone marrow of HIV-positive indi-
viduals (Longhi et al., 2007; Manning et al., 2007). Recently, PARV4
DNA was detected in cerebrospinal ﬂuid of two children with encepha-
litis of unknown etiology (Benjamin et al., 2011). However, the disease
association of PARV4 remains unclear (Brown, 2010; Simmons et al.,
2011).
HBoV has been classiﬁed as a member in the genus Bocavirus based
on the similarity of its genome sequence with those of the two animal
bocaviruses, minute virus of canines (MVC) and bovine parvovirus
type 1 (BPV1) (Allander et al., 2005; Tijssen et al., 2011). However,
the known PARV4 incomplete genome, which lacks information of
the terminal repeats, does not show a close relationship to any of the
known parvoviruses in the genera of the family Parvoviridae that
have been classiﬁed to date, but represents a deeply rooted lineage be-
tween avian dependoviruses and bovine parvovirus type 3 (Jones et
al., 2005). Notably, PARV4-like viruses were detected in animals in
Hong Kong, which were subsequently named as porcine and bovine
hokoviruses (Lau et al., 2008). Later, a related porcine hokovirus was
identiﬁed in wild boars (Adlhoch et al., 2010), and PARV4-like viral
DNA was detected in plasma samples from chimpanzees and gorillas
in Cameroon (Sharp et al., 2010). Phylogenetic analysis of the PARV4 ge-
nome togetherwith those of hokoviruses has shown a close resemblance
Fig. 1. Replication of the construct p5TRPARV4 in 293 cells. 293 cells were transfected
with p5TRPARV4, pAV5Rep78 and pHelper, or pSKPARV4 alone. Hirt DNA was
extracted from the cells 48 h post-transfection and digested with DpnI (DpnI+) or
without DpnI (DpnI−). The DNA samples were then subjected to Southern blot analy-
sis using the PARV4 NSCap probe (nt 127–5268). 10 ng of the probe template DNA was
treated in parallel as a DpnI digestion control (lanes 1 and 2).
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These ﬁndings have led to the proposed classiﬁcation of the PARV4 and
PARV4-like viruses as members in a new genus called Partetravirus in
the family Parvoviridae by the International Committee on Taxonomy
of Viruses (ICTV) (Tijssen et al., 2011).
Little is known about the gene expression of PARV4 and the function
of PARV4 proteins. Since the PARV4 has not been cultured in vitro, and
the full-length genome with terminal repeats has not been sequenced,
we proﬁled the gene expression of PARV4 by transfecting a replication-
competent PARV4 genome, which harbors AAV5-inverted terminal re-
peats (ITRs) at two ends, in 293 cells expressing AAV5 Rep78 protein
and the necessary adenovirus gene products. The function of the large
nonstructural protein NS1 was studied in detail for its role in inducing
cytopathic effects in ex vivo-generated human hematopoietic stem
cells (CD34+ HSCs). In addition, the VP1 unique region (VP1u) was pu-
riﬁed and tested in vitro for its hypothesized phospholipase A2 (PLA2)-
like activity.
Results
Constructing a replication-competent clone of PARV4 in the context of
AAV5 ITRs
We ﬁrst cloned nucleotide nt 127–5268 of the PARV4 genome
(GenBank accession no.: NC_007018) into vector pCR2.1, which en-
compasses a coding region with two large open reading frames
(ORF) and a portion of the terminal repeats at the 5′ and 3′ ends
(Jones et al., 2005). This incomplete PARV4 genome lacks the termi-
nal repeats at two ends, and therefore will not replicate in any cell
culture system. To determine the transcriptional proﬁle of PARV4 in
a replication-competent system, we incorporated the incomplete
PARV4 genome into the context of AAV5 ITRs, which resulted in plas-
mid p5TRPARV4. It replicated efﬁciently in 293 cells that expressed
AAV5 Rep78 protein and necessary Ad5 gene products (i.e., E2,
E4orf6 and VA RNA from the pHelper plasmid) (Guan et al., 2008)
(Fig. 1, lane 4). In contrast, the pSKPARV4 clone, which did not con-
tain the AAV5 ITRs, did not replicate in 293 cells (Fig. 1, lane 8).
Thus, we used the p5TRPARV4 construct for further analysis of
PARV4 gene expression.
5′/3′ rapid ampliﬁcation of cDNA ends (RACE) and reverse transcription
(RT)-PCR identiﬁcation of the transcription units of the PARV4 genome
We used total RNA extracted from 293 cells that had been co-
transfected with p5TRPARV4, pAAV5Rep78, and pHelper to analyze
PARV4 mRNA transcripts. The 5′ RACE using the primer Rnt960 gener-
ated a predominant band of ~690 nts (Fig. 2A, lane 1). Sequence analy-
sis of this band revealed that mRNA transcripts spanning the region
from the 5′ end to nt 960 initiated at nt 262. The 5′ RACE with primers
Rnt3840 and Rnt3440 producedmajor bands of ~700 nts and ~300 nts,
andminor bands of ~600 nts and ~200 nts, respectively (Fig. 2A, lanes 2
and 5, respectively). Sequence analysis of the major bands revealed the
presence of a 5′ end of PARV4mRNAs at nt 1950, and splicing sites of D2
donor at nt 2060, A2 acceptor at nt 2309, D3 donor at nt 2367, and A3
acceptor at nt 3329. In addition, sequence analysis of the minor bands
conﬁrmed the 5′ end of PARV4 mRNAs at nt 1950, and revealed the
splicing sites of D3m donor at nt 2013 and A3 acceptor at nt 3329.
Taken together, these results demonstrated the existence of two pro-
moters at map unit 6 and 38, namely P6 and P38, which transcribed
PARV4mRNAs of ORFs at the left and right hands of the PARV4 genome,
respectively. The 3′ RACE with primer Fnt3518 produced two predom-
inant bands of ~1500 nts and ~300 nts (Fig. 2A, lane 7). Sequence anal-
ysis of these two bands revealed that they terminated at nt 5149 and nt
3771, respectively, suggesting that PARV4mRNAs are polyadenylated at
either nt 5149 or nt 3771.More extensive RT-PCR analysis using different sets of primers
followed by sequencing also showed the same results as those obtained
by 5′/3′RACE,which conﬁrmed the donor and acceptor sites for alterna-
tive splicing of PARV4mRNAs generated from the P6 and P38 promoters
(Fig. 2A, lanes 3, 4, and 6). Sequence analysis of the DNA fragments am-
pliﬁed by PCR using primers Fnt283 and Rnt2060 revealed an intron
that lies in the NS1-encoding region from the D1 donor (nt 418) to
the A1 acceptor sites (nt 1630).
Taken together, these data provide the locations of all transcription
units in the PARV4 genome by 5′/3′ RACE and RT-PCR, which are dia-
gramed in Fig. 2B. The sequence results of the ampliﬁed fragments are
shown in detail in Table 1.
RNase protection assay (RPA) analysis of PARV4 mRNA transcripts
To determine the relative abundance of each PARV4 mRNA tran-
script, we used 8 anti-sense probes to protect individual transcript.
A schematic diagram of the probes with their putatively protected
bands and respective sizes is shown in Fig. 3A.
Probe P1, which spanned the P6 promoter and D1 donor site, pro-
tected bands of 219 and 157 nts in sizes. These bands conﬁrmed the
mRNA initiation site at nt 262 and the D1 donor site at nt 418. Nota-
bly, the spliced band (157 nts) at the D1 donor site accounted for less
than 5% of the total protected bands (Fig. 3B, lane 2), suggesting that
mRNA splicing at the D1 site is rather poor.
Probe P3, which spanned the A1 acceptor site of the ﬁrst intron,
protected bands of 320 and 131 nts in sizes (Fig. 3B, lane 10). The pro-
tected band of 131 nts conﬁrmed the position of the A1 acceptor site
at nt 1630. Similar to what was observed at the D1 donor site, only a
few PARV4 mRNAs were spliced at the A1 acceptor site, suggesting
Fig. 2. 5′/3′ RACE and RT-PCR analyses of PARV4 mRNAs. Total RNA was isolated from 293 cells co-transfected with p5TRPARV4, pAV5Rep78, and pHelper and subjected to reverse
transcription. The cDNA was then subjected to 5′/3′ RACE analysis or ampliﬁed with PARV4-speciﬁc primers. (A) Ampliﬁed DNA fragments were electrophoresed on 2% agarose gel
and visualized using ethidium bromide staining. (B) Primer sets used for PCR ampliﬁcation are depicted, and the transcription units identiﬁed, with the promoters (P6 and P38),
splice donor (D1, D2, D3 and D3m) and acceptor (A1, A2 and A3) sites, and polyadenylation signals [(pA)p and (pA)d], are shown. LTR, left terminal repeat; RTR, right terminal
repeat.
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D1–A1 sites.
Probe P4, which spanned the P38 promoter and D3m donor site,
protected bands of 377, 330, 111 and 64 nts in sizes (Fig. 3B, lane 3).
Probe P5, which spanned the P38 promoter, D3m and D2 donor
sites, protected bands of 240, 211, 140, 111 and 64 nts in sizes
(Fig. 3B, lane 4). These bands conﬁrmed the locations of the P38 pro-
moter as well as the D3m and D2 donor sites at nt 1950, 2013 and
2060, respectively. Only ~5%ofmRNAs generated from the P38promoter
were spliced at the D3m donor site, which resulted in a band of 64 nts.
The majority of the P38-generated mRNAs were spliced at the D2 site,
which produced a band of 111 nts.
Probe P6, which spanned the A2 acceptor and the D3 donor sites,
protected bands of 233, 120, and 59 nts in sizes. These bands con-
ﬁrmed the presence of the PARV4 mRNAs spliced at the A2 acceptor
site (nt 2309) and the D3 donor site (nt 2367) (Fig. 3B, lane 5). A pu-
tative band of 172 nts, which refers to the transcripts that are spliced
at the A2 site but not at the D3 donor site, was not detected, suggesting
that the PARV4 mRNAs that were spliced at the A2 site were spliced
concurrently at the D3 donor site.Probe P7, which spanned the A3 acceptor site, protected two
bands of 232 and 112 nts in sizes, respectively. Thus, the A3 acceptor
site was mapped to nt 3329 (Fig. 3B, lane 6). The ratio of unspliced vs.
spliced PARV4 mRNA transcripts across this region was ~1:4.
Probe P8 was used to conﬁrm the internal poly A signal (pA)p site
(Fig. 3B, lane 7). No band of ~170 nts in size was apparent, which sug-
gests that the (pA)p site at nt 3771 detected by 3′ RACE is not signiﬁ-
cantly used for processing PARV4 pre-mRNA. Probe P9 protected a
major band at ~183 nts, which was produced when PARV4 mRNAs
were terminated at the (pA)d site, conﬁrming the predominant polya-
denylation site of PARV4 mRNA transcripts at nt 5149 (Fig. 3B, lane 8).
Northern blot analysis of PARV4 mRNA transcripts
Hybridization of PARV4 mRNAs with the Cap probe (nt 3841–5200)
detected four major bands (Fig. 4A, lane 3), which were putatively
NS1a-encoding R1a mRNA (~4.0 kb), NS1b-encoding R1b mRNA
(~5.0 kb), VP1-encoding R3 mRNA (~3.2 kb), and VP2-encoding R4
and R5 mRNAs (~2.0 kb). The putative NS2-encoding R2 mRNA
(~2.4 kb) had a much lower expression level and was not clearly
Table 1
Sequencing results of the DNA bands obtained from 5′/3′ RACE and RT-PCR.
Lane Analysis Primersa Bands Identiﬁed transcriptsa
1 5′ RACE d(G)16-R
nt960
a P6 nt262-960
2 5′ RACE d(G)16-R
nt3840
a P38 nt1950-2060Δ2309-2367Δ3329-3840
b P38 nt1950-2013Δ3329-3840
3 RT-PCR F nt283-R
nt2060
a P6 nt283-2060
b P6 nt283-418Δ1630-2060
4 RT-PCR F nt1441-R
nt2354
a non-speciﬁc
b P6 nt1441-2354
c P6 nt1441-2060Δ2309-2354
5 5′ RACE d(T)18V-R
nt3440
a P38 nt1950-2060Δ2309-2367Δ3329-3440
b P38 nt1950-2013Δ3329-3440
c Primer dimers
6 RT-PCR F nt283-R
nt3440
a P6 nt283-2060Δ2309-2367Δ3329-3440
b P6 nt283-418Δ1630-2060Δ2309-
2367Δ3329-3440
c P6 nt283-418Δ1630-2013Δ3329-3440
d P6 nt283-418Δ3329-3440
7 3′ RACE F nt3518-d(T)
18V
a (pA)d at nt 5149
b (pA)p at nt 3771
c Non-speciﬁc
“Δ” denotes intron.
a Nucleotide numbers shown refers to Genbank accession no.: NC_007018.
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supposed to detect the R2 mRNA, or in lane 3, where the Cap probe
was used, in Fig. 4A. The NS probe was included to detect all transcripts
generated from the P6 promoter; however, this probe only revealed a
single major band, the R1a mRNA at ~4.0 kb. There were two smear
areas above and below the R1a band, which potentially correspond to
the R1bmRNA at ~5.0 kb andR2 (R2a+R2b)mRNAs at ~2.4 kb, respec-
tively (Fig. 4A, lane 2).
Analysis with the PARV4 genome probe (NSCap) showed an overall
RNA proﬁle generated from transfection of p5TRPARV4 (Fig. 4A, lane 4).
Five major species of mRNA transcripts were observed, which were
consistent in size with those detected when using the Cap probe and
predicted to encode NS1 (R1a and R1b), VP1 (R3), and VP2 (R4 and
R5). The R4/R5 mRNAs were the most abundant transcripts and consti-
tuted ~80% of the total viral mRNAs.
Accordingly, we generated a genetic map of PARV4 as a summary
of the results obtained from 5′/3′ RACE, RT-PCR, RPA, and Northern
blot analyses (Fig. 4B). The ﬁve major PARV4 mRNA transcripts and
two minor transcripts (R2a and R2b) are depicted with their respec-
tive sizes, abundance by percentage, and encoded proteins.
Expression strategy of PARV4 proteins
We next examined protein expression of PARV4 by transfecting.
To determine whether the NS1a or NS1b protein is expressed after
transfection of p5TRPARV4 and pSKPARV4 in 293 cells, we expressed
NS1a and NS1b individually as size controls (Fig. 5A, lanes 5 and 6).
We found that NS1a was clearly detected, but not NS1b, in both
p5TRPARV4- and pSKPARV4-transfected cells (Fig. 5A, lanes 2 and 4).
The bands of bothNS1awere slightly lower than the one as the size con-
trol, which are likely due to the unevenmigrations of NS1a in each lane
(Fig. 5A). Although the predicted size of the NS1a protein is 66 kDa
(Fig. 4B), it appeared larger than 72 kDa (~80 kDa) in the blot, which
was likely due to a modiﬁcation of the NS1 protein (e.g., phosphoryla-
tion) (Nuesch et al., 1998).
The anti-N-NS1 antibody used for Western blot was produced
against the N-terminus (aa 27–44) of the NS1 protein (Fig. 4B),
which is potentially able to detect both NS1 and NS2 proteins. How-
ever, we did not detect speciﬁc bands around 7 kDa, which should
have corresponded to the putative NS2 protein, using a high percent-
age (15%) PAGE gel (data not shown). These results indicated that the
NS2 protein is likely expressed at a very low level.Using the anti-C-VP2 antibody raised against the C-terminus (aa
500–552) of the VP2 protein, we detected a major band at a molecu-
lar weight of ~65 kDa, which corresponded to the VP2 protein, in
both p5TRPARV4 and pSKPARV4-transfected cells (Fig. 5B, lanes 2
and 4). Notably, VP1, which has a predicted molecular weight of
101 kDa, was not detected. However, we observed a minor band
around 90 kDa above the VP2 band, which could be the VP1 protein
translated from the second AUG (nt 2531) or the third AUG (nt
2678) on the VP1-encoding R3 mRNA (Fig. 4B). However, it is also
possible that the band of ~90 kDa was a cleaved product of the VP1
protein of 101 kDa, since the capsid proteins of other parvoviruses
have been reported to be cleaved (Cheng et al., 2009; Farr et al.,
2006).
Both the PARV4 NS1a and NS1b proteins induce cell cycle arrest at G2/M
phase
As shown in other genera of parvoviruses, the large nonstructural
protein NS1 or Rep78 protein is able to induce cell cycle arrest (Chen
and Qiu, 2010), which is also a hallmark of B19V infection of primary
erythroid progenitor cells (Wan et al., 2010). Since PARV4 was pre-
viously detected in human bone marrow (Longhi et al., 2007; Man-
ning et al., 2007), we examined the effect of PARV4 NS1 on the cell
cycle progression of CD34+ HSCs. We ﬁrst performed a sequence
alignment among PARV4 NS1, B19V NS1, and AAV2 Rep78 proteins
(Fig. 6A). Highly conserved regions were identiﬁed in the helicase
motifs (the four sites of Walker boxes, A, B, B′ and C sites (Jindal et
al., 1994; Momoeda et al., 1994; Walker et al., 1997)). Therefore,
we introduced mutations in boxes A and B of both NS1a and NS1b to
explore the potential role of the helicase motifs of NS1 in disturbing
cell cycle progression.
We transduced lentiviruses in CD34+ HSCs in order to express
NS1a and NS1b. At 48 h post-transduction, we analyzed the cell
cycle progression using ﬂow cytometry. As shown in Fig. 6B, an obvi-
ous G2/M arrest (pb0.01) was observed in both NS1a and NS1b-
expressing CD34+ HSCs compared to RFP-expressing cells. Notably,
both NS1a(mA+B) and NS1b(mA+B), which bear the mutations in
boxes A+B, signiﬁcantly rescued the G2/M arrest (pb0.01, Fig. 6C).
The expression levels of NS1a, NS1b and their mutants in transduced
cells were quantiﬁed at similar levels as shown with mean ﬂuores-
cence intensity in Fig. 6D. These results demonstrated that the
PARV4 NS1a/b proteins are capable of inducing a G2/M arrest in
NS1-expressing cells. Thus, these data reveal a remarkable feature of
the PARV4 NS1, which is similar to that seen with B19V infection of
primary erythroid progenitor cells (Wan et al., 2010) and clearly in-
volves the predicted helicase motifs.
The PARV4VP1 unique region does not exhibit phospholipase A2-like activity
in vitro
The VP1 unique region (VP1u) of parvoviruses functions like PLA2
with conserved motifs, which is critical for virus infection (Zadori et
al., 2001). We ﬁrst aligned the PARV4 VP1u with that of B19V, and
identiﬁed conserved PLA2 motifs (Fig. 7A). To examine the PLA2-like
activity of the PARV4 VP1u, three forms of VP1u (1M-VP1u, 52M-
VP1u, and 101M-VP1u) were puriﬁed (Fig. 7B), which originated
from three different methionines of the putative VP1u. This approach
was taken because we had not determined the start AUG for transla-
tion of PARV4 VP1. Puriﬁed B19V VP1u and GST proteins were used as
positive and negative controls, respectively. As seen in Fig. 7C, both
B19V VP1u and bee venom exhibited signiﬁcant PLA2-like activity
(Dorsch et al., 2002); however, none of the PARV4 VP1u proteins
possessed PLA2-like function in vitro, implying that either the PARV4
VP1u requires a structural conformation for PLA2-like activity or PLA2-
like activity is not required for PARV4 infection.
Fig. 3. Transcription mapping by RNase protection assays (RPAs). (A) Schematic diagram of the PARV4 genome and the probes used for the RPA. The PARV4 genome is depicted with
the transcription units. Probes used for the RPAs are shown with their respective nucleotide numbers, together with the bands that they are expected to protect with the predicted
sizes. Spl, spliced mRNAs; Unspl, unspliced mRNAs; RT, mRNAs read through the polyadenylation site. (B) Mapping of the PARV4 transcripts by RPA. 10 μg of total RNA was isolated
from 293 cells transfected with p5TRPARV4, pAV5Rep78, and pHelper, and were protected by PARV4 probes P1 and P3-9. Lanes 1 and 9, 32P-labeled RNA markers with sizes indi-
cated. Bands detected are designated in each lane.
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Fig. 4. Transcription proﬁle of PARV4. (A) Northern blot analysis. Total RNAwas isolated from 293 cells transfected with p5TRPARV4, pAV5Rep78, and pHelper, and used for Northern
blot analysis. The blots were hybridized to three PARV4 DNA probes (NSCap, NS, and Cap), respectively. Bands of mRNA detected by each probe are designated in each lane. The RNA
marker ladder is shown in lanes 1 and 5. The asterisk denotes a likely non-speciﬁc band detected by all three probes. (B) Transcriptionmap of PARV4. The PARV4 genome is shown to
scale, with transcription landmarks indicated. Major mRNA species detected in RT-PCR, RPA, and Northern blot assays are diagrammed to display their identities and respective sizes
in the absence of the polyA tail. The putative ORFs that each can encode are also diagramed in boxes, and the predicted sizes (kDa) of translated proteins are indicated on the right. The
relative abundance of each mRNA and proteins detected by transfection are also shown on the right. Potential AUG usage for VP1 translation and peptides used for production of
antibodies are depicted. N/D, not determined or not detected.
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With a recurrent pandemic of newly emerging viruses worldwide,
strong interest has been drawn on uncovering novel viruses that can
potentially infect humans. The newly identiﬁed human parvoviruses
HBoV and PARV4 have been widely found to persist in humans
(Allander et al., 2005; Brown, 2010; Jones et al., 2005). In this study,
we revealed the basic gene expression proﬁle of PARV4, which not
only has important clinical signiﬁcance, but also identiﬁed its position
as a member in the newly formed genus Partetravirus in the family
Parvoviridae (Tijssen et al., 2011).The characterized transcription map of PARV4, which resulted from
transfection of a replication-competent PARV4 clone, is similar to those
of the parvoviruses in the genus Parvovirus (Qiu et al., 2006b). Two pro-
moters, P6 and P38, were used to transcribe NS-encoding and VP-
encodingmRNAs, respectively. In contrast to the parvoviruses in genera
Amdovirus, Bocavrius, and Erythrovirus, PARV4 does not employ internal
polyadenylation for pre-mRNA processing (Ozawa et al., 1987; Qiu et
al., 2006a, 2007a; Sun et al., 2009). Although NS2 protein was not
detected after transfection, R2 mRNAs, which are transcribed from the
P6 promoter and spliced in the NS1-encoding region, likely encode
NS2 protein during PARV4 infection similar to members of the genus
Fig. 5. Western blot analysis of PARV4 proteins. 293 cells were transfected with plas-
mids as indicated. At 48 h post-transfection, the cells were harvested and lysed for
Western blotting using polyclonal antibodies anti-N-NS1 (A) and anti-C-VP2 (B), re-
spectively. The blots were reprobed using an anti-β-actin antibody. The identities of
detected proteins are shown to the right on the blot. Untransfected cells were used
as a control. The asterisk indicates bands that were likely degraded from VP2.
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virus (CPV). PARV4-like parvoviruses have emerged in animals world-
wide (Adlhoch et al., 2010; Lau et al., 2008; Sharp et al., 2010);
however, like PARV4, noneof the PARV4-like parvoviruses has been cul-
tured in vitro as yet, and infectious clones have not been established.
We have employed an AAV5 ITRs-supported replication system to
study gene expression of parvoviruses B19V and HBoV, which closely
reﬂects the proﬁles during virus infection (Chen et al., 2010a; Guan et
al., 2008). We realize that the transcription proﬁle of PARV4 generated
from this AAV5 ITRs-supported replication system might not fully de-
pict the proﬁle during PARV4 infection; however, our characterization
of the gene expression proﬁle of PARV4 within this artiﬁcial replication
systemwill lay a fundamental guidance for future study of PARV4 gene
expression during infection.
The large nonstructural protein NS1 or Rep78 of parvoviruses is es-
sential for viral DNA replication (Cotmore and Tattersall, 2005a), tran-
scriptional transactivation (Ahn et al., 1992; Legendre and Rommelaere,
1994), and encapsidation of the viral genome (Cotmore and Tattersall,
2007). In addition, it causes cytopathic effects of infected cells by inducing
cell cycle arrest and apoptosis (Chen and Qiu, 2010). The PARV4 NS1a
protein is encoded from a spliced form of R1 mRNA (R1a, Fig. 4B) and
was clearly detected after transfection. Although the NS1b protein was
not detectable in PARV4-transfected cells, the R1b mRNA was clearly
detected (Fig. 4A). Therefore, PARV4 NS1a is likely the major NS1
protein expressed during infection, while NS1b is produced at arelatively low level. Parvoviruses use different strategies to express
their NS1 proteins. Some NS1 proteins are expressed from unspliced
mRNAs (e.g., B19V and AAVs) (Ozawa et al., 1987; Qiu et al., 2002).
Some parvoviruses only express one form of NS1 (e.g., B19V and
MVM) (Cotmore and Tattersall, 2005b; Ozawa et al., 1987), but some
others express multiple isoforms that possess different functions (Di
and Chiorini, 2003). NS1a and NS1b proteins differ at the C-termini
(Fig. 4B). The NS1b C-terminus-encoding region lies in the intron that
spans the D2 and A2 splice sites, which is only used to encode the
NS1b C-terminus. Since the NS1 C-terminus of parvoviruses has tran-
scriptional transactivation function (Legendre and Rommelaere,
1994),we hypothesize that bothNS1a andNS1bproteins are expressed,
and that the NS1b is also required for the life cycle of PARV4 during in-
fection. But one possibility still could not be ruled out that the R1b tran-
script could be a nuclear precursor mRNA that may not be used for
translation of NS1b protein. If a virus infection system is available, the
existence of NS1b protein could be easier to be proved.
We found that both NS1a and NS1b induced G2/M arrest in NS1-
expressing hematopoietic stem cells (Fig. 6). This characteristic is
quite similar to that of B19V NS1 (Wan et al., 2010). Amino acid align-
ment showed that PARV4 NS1 contains conserved helicase motifs
(Jindal et al., 1994; Momoeda et al., 1994; Walker et al., 1997). Muta-
tions of the helicase motifs abolished the G2/M arrest, suggesting that
the helicase motifs of NS1 are involved in the G2/M arrest induced by
PARV4 NS1. It has been shown that the helicase motifs of B19V NS1
are critical for the induction of apoptosis (Momoeda et al., 1994). Be-
sides, the nuclear localization signal (NLS) has been shown to be im-
portant for B19V NS1 to induce G2/M arrest in primary erythroid
progenitor cells (Wan et al., 2010). It is interesting to hypothesize
that the mechanism underlying PARV4 NS1-induced G2/M arrest
may differ from that of B19V NS1. We also found that PARV4 NS1 in-
duced G2/M arrest in 293 T and HeLa cells (data not shown). Thus we
believe that PARV4 NS1 induces G2/M arrest in PARV4-infected cells.
Further studies are needed to prove that NS1 can disturb the cell cycle
and elucidate its mechanism during PARV4 infection.
Parvovirus is non-enveloped, and has an icosahedral capsid formed
by themain structural VP2 protein and theminor structural VP1 protein
with PLA2-like activity, which is a lipolytic enzyme lyingwithin the cap-
sid (Tsao et al., 1991). The PLA2-like activity is required for efﬁcient pen-
etration of virions through the cellularmembrane (Farr et al., 2005) and
for the transfer of the viral genome from the endosomes or lysosomes
into the nucleus (Zadori et al., 2001). However, the structural conforma-
tion of VP1u in the virions among different genera of parvoviruses could
bedifferent (Anderson et al., 1995; Cotmore et al., 1999; Rosenfeld et al.,
1992). In our study, none of the three forms of puriﬁed PARV4 VP1u
appeared to exhibit PLA2-like activity in vitro, while B19V VP1u exhib-
ited a strong activity (Dorsch et al., 2002), which was somewhat unex-
pected. This result could be due to either the requirement of a speciﬁc
structural conformation of PARV4 VP1u or the possibility that PARV4
utilizes certain novel mechanisms to penetrate through cellular mem-
branes without the need of PLA2-like activity.
In conclusion, as a representative member in the new genus
Partetravirus in the family Parvoviridae, PARV4 shares characteristics
of transcription and protein expression with the parvoviruses in the
genus Parvovirus. PARV4 NS1 protein shares features with B19V NS1
protein and can induce G2/M arrest in primary hematopoietic cells
and certain cell lines. Therefore, our study has shown for the ﬁrst
time the detailed transcription map of PARV4, which can be beneﬁ-
cial for subsequent study of PARV4 infection.
Materials and methods
Cells and transfection
HEK-293 (ATCC-1573) cells were maintained in Dulbecco's modi-
ﬁed Eagle's medium with 10% fetal calf serum (FCS) in 5% CO2 at
Fig. 6. The helicase motifs of the PARV4 NS1 are responsible for G2/M arrest induced by PARV4 NS1 protein. (A) Comparison of the NS1 helicase motifs. The amino acid sequences of
B19V NS1, AAV2 Rep78, and PARV4 NS1 were aligned using ClustalW2 (Larkin et al., 2007). The alignment of aa 327–417 of B19V NS1, aa 333–423 of AAV2 Rep78, and aa 333–423
of PARV4 NS1 is depicted with identical amino acids shown by the asterisk, while homologous amino acids are shown as two dots under the amino acid. Conserved motifs (Walker
boxes A, B, B′, and C) are underlined in red, while the mutated regions of boxes A and B are marked in green. (B&C) PARV4 NS1 protein induces G2/M arrest. (B) CD34+ HSCs were
transduced with lentiviruses to express proteins as indicted. At 48 h post-transduction, RFP- or NS1-expressing cells were selectively gated for anti-Flag staining, followed by DAPI
staining for cell cycle analysis. The cell cycle patterns of both NS1/RFP-positive and NS1/RFP-negative cells are shown in parallel. In each panel, the percentages of cells in the G1, S,
and G2/M phases are indicated, respectively (top left). A representative experiment is shown. (C) The percentage of RFP-expressing cells in G2/M was arbitrarily set as 1. Relative
values are shown with average and standard deviation from at least three independent experiments. P values were determined using a Student's t test. (D) Expression levels of
PARV4 NS1 proteins. The expression levels of RFP and NS1 as mean ﬂuorescence intensity (MFI) were analyzed by ﬂow cytometry in lentivirus-transduced (NS1/RFP+) cells at
48 h post-transduction. The reference line is selected arbitrarily to show the relative position of the NS1/RFP-positive and negative peaks, and Bkg (background) represents the
secondary antibody only control. A representative experiment is shown to the left. Relative MFI values were determined as fold changes of MFI of NS1/RFP+ cells compared to
that of Bkg, and are shown to the right with average and standard deviation.
66 S. Lou et al. / Virology 422 (2012) 59–6937 °C. Human hematopoietic stem cells were purchased from the Na-
tional Disease Research Interchange (NDRI, Philadelphia, PA). CD34+
HSCs were cultured in StemSpan serum-free expansion medium
(SFEM; StemCell Technologies Inc., Vancouver, Canada) as previously
described (Chen et al., 2010b), and stored in liquid nitrogen on day 4
of the culture. The day 4 stock of CD34+ HSCs was then thawed and
expanded ex vivo in SFEM until day 6 for lentivirus transduction.
Transfection was performed using the Lipofectamine™ and Plus™
reagent (Invitrogen, Carlsbad, CA) or LipoD293 transfection reagent
(SigmaGen Laboratories, Rockville, MD) following the manufacturers'
instructions.Plasmid construction
(i) Clones of the PARV4 genome: A primer based on the common
repeated sequence in both the 5′ and 3′ terminal repeats of the
PARV4 genome was used to amplify the full encoding sequence.
DNA extracted from a patient's serumwas ampliﬁed with primer
HP4-FL (5′-WCG TAT TTC CGC TTC CGG TC-3′), and ExTaq DNA
polymerase (TakaraMirius Bio., Madison,WI) using the following
ampliﬁcation parameters: 94 °C for 2 min, and then 30 cycles of
92 °C for 40 s, 52 °C for 40 s, and 68 °C for 4 min. A ﬁnal extension
was performed at 75 °C for 5 min. The PCR product was cloned
Fig. 7. The PARV4 VP1 unique region does not exhibit phospholipase A2-like activity in vitro. (A) Comparison of B19V VP1u and PARV4 VP1u. The PARV4 VP1 and potential unique
regions are diagramed. The alignment of PLA2-conserved motifs of B19V VP1u and three forms of PARV4 VP1u is depicted, with identical amino acids shown as an asterisk and ho-
mologous amino acids shown as two dots. (B) SDS-PAGE analysis of puriﬁed PARV4-VP1u and B19V VP1u proteins. Five microliter of each puriﬁed protein and BSA standards was
analyzed on SDS-10%PAGE gel. The gel was stained using Coomassie blue. A protein maker is shown. (C) PARV4 VP1u does not exhibit PLA2-like activity. An in vitro sPLA2 assay kit
was used to test PLA2-like activity of various substrates as indicated on the right. The PLA2-like activity is shown as a value of the absorbance at 414 nm at various time points. BLK,
blank.
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resulted in pCR2.1-PARV4. The PARV4 sequence was conﬁrmed
to be from nt 127 to 5268 (GenBank accession no.: NC_007018).
The p5TRPARV4 plasmid, which contained the PARV4 sequence
ﬂanked by AAV5 ITRs at two ends, was constructed by ligating
PARV4 nt 127–5268 into the EcoRV-digested AAV5 ITRs-
containing plasmid pAV5ITR (Guan et al., 2008). The PARV4 se-
quence was also cloned into a KpnI/EcoRI-digested pBluescript
SK(+)vector (Agilent, Santa Clara CA),which created the plasmid
pSKPARV4.
(ii) Lentiviral vectors: Two PARV4 NS1 sequences, NS1a (nt
283–2060/2309–2345) and NS1b (nt 283–2774), as well as an
RFP-coding sequence (Chen et al., 2010c), were tagged with the
Flag-encoding sequence at the C-terminus and cloned into a
BamHI/BsrG-digested pLenti-CMV-IRES-GFP-WPRE vector (Chen
et al., 2011), which resulted in pLenti-NS1a, pLenti-NS1b, and
pLenti-RFP, respectively. In addition, two helicase motifs (box
A+B) of the NS1 were mutated from amino acid number (aa)
337STGK340 to AAAA and 378EE379 to AA, resulting in plasmids
pLenti-NS1a(mA+B) and pLenti-NS1b(mA+B), respectively.
(iii) Probe constructs for RNase protection assay: RPA probe clones,
P1 and P3-9, were constructed by ligating the following regions of
PARV4 into pGEM3Z (Promega, Madison, WI) at BamHI/HindIII
sites: nt 219–480 (P1), nt 1441–1760 (P3), nt 1684–2060 (P4),
nt 1921–2160 (P5), nt 2248–2480 (P6), nt 3209–3440 (P7), nt
3601–3834 (P8), and nt 4967–5201 (P9).
(ii) Constructs for glutathione S-transferase (GST)-fusion protein ex-
pression. The PARV4 NS1 N-terminus (aa 27–44) and the VP2
C-terminus (aa 500–552) were cloned into BamHI/XhoI-digested
pGEX4T3 (GE Healthcare, Piscataway, NJ) as pGEX-N-NS1 and
pGEX-C-VP2, respectively.PARV4 VP1u-encoding sequences, which originate from the methio-
nine (M) at three different positions, nt 2378 (1M-VP1u), nt 2531 (52M-
VP1u) and nt 2678 (101M-VP1u), respectively, were cloned into a
BamHI/XhoI-digested pGEX4T3 vector as pGEX-1M-VP1u, pGEX-
52M-VP1u and pGEX-101M-VP1u, respectively. As a control, B19V
VP1u (nt 2624–3304, accession no: AY386330) was also cloned into
pGEX4T3 to create pGEX-B19VVP1u.
The sequences of all the clones were conﬁrmed at MCLAB (South
San Francisco, CA).
Southern blot analysis
Hirt DNA was extracted from p5TRPARV4- and pSKPARV4-
transfected 293 cells, andDpnI digestion and Southern blottingwere per-
formed as previously described (Guan et al., 2008) using the PARV4
NSCap probe template (nt 127–5268). Signals were developed by expos-
ing the blot to an X-ray ﬁlm.
RNA isolation and RNA analysis
p5TRPARV4 was co-transfected with pAV5Rep78 and pHelper
plasmids into 293 cells as previously described (Guan et al., 2008).
Total RNA was isolated 48 h later using Trizol® reagent (Invitrogen).
RNase protection assay
Probes were generated from EcoRI-digested templates by in vitro
transcription with T7 polymerase, using a MAXIscript kit (Ambion,
Austin, TX) following the manufacturer's instruction. RPAs were per-
formed as previously described (Naeger et al., 1992; Schoborg and
Pintel, 1991). RPA signals were quantiﬁed with a Typhoon 9700 Phos-
phorImager and ImageQuant TL software v2005 (GE Healthcare).
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after adjusting the number of 32P-labeled uridines (U) in each protected
fragment, as previously described (Schoborg and Pintel, 1991).
Northern blot analysis
Northern blot analysis was performedwith an input of 5 μg of total
RNA as previously described (Pintel et al., 1983; Qiu et al., 2002). Blots
were hybridized with the PARV4 NS, Cap and NSCap probes, which
were ampliﬁed PARV4 DNA fragments that spanned nt 283–560, nt
3841–5200 and nt 127–5268, respectively. Signals were developed
and analyzed with a Typhoon 9700 PhosphorImager.
5′/3′ RACE
The 5′ and 3′ RACE was performed following the instructions of the
RACE kit (Roche, Nutley, NJ). The primers for 5′ RACE were as follows:
forward primers: d(G)16 (5′-GGC CAC GCG TCG ACT AGT ACG GGG
GGG GGG GGG GGG-3′), or d(T)18V (5′-CGC GGA TCC TTT TTT TTT
TTT TTT TTT A/C/G-3′); reverse primers: Rnt960 (5′-CAT GAA TCT TTG
TGT TCC-3′), Rnt3440 (5′-GCA AGG CCG GGT CAG ACT CG-3′), and
Rnt3840 (5′-CTT GCA GAA TCA GAA ACA G-3′). The primers for 3′
RACE were as follows: Fnt3518 (5′-ATA GGT GGA ACT AGT TTT TCT
GAT TCT GTA GTT-3′) and d(T)18V.
RT-PCR
The cDNA was synthesized as previously described (Guan et al.,
2008). Primers used for RT-PCR are diagramed in Fig. 2B. The se-
quences were as follows: Fnt283 (5′-ATG GAC GCT CCT GCC TGG
ATT-3′), Fnt1441 (5′-GTT GAA GTA GCC AAA GCT GTG -3′), Rnt2060
(5′-CTT TCA GCA GTT TCG TCA-3′), and Rnt2354 (5′-TGA AGC TTG
TTA GTC TTC TGC-3′). PCR was performed with Vent®Taq DNA poly-
merase (NEB, Ipswich, MA) using the following ampliﬁcation param-
eters: 94 °C for 2 min, followed by 30 cycles of 92 °C for 45 s, 52 °C for
60 s, and 72 °C for 1 min. A ﬁnal extension was performed at 72 °C for
10 min. The ampliﬁed DNA fragments were separated on a 2% agarose
gel, and all bands were excised and puriﬁed by using a gel extraction
kit (Qiagen, Valencia, CA). The ﬁnal products were sequenced at
MCLAB.
Production of antibodies against PARV4 proteins
GST-N-NS1 and GST-C-VP2 proteins were expressed in Escherichia
coli BL21 cells transformed with pGEX-N-NS1 and pGEX-C-VP2, re-
spectively, and were puriﬁed using a GSTrap FF 1-ml column (GE
Healthcare) on the Biologic LP system (Bio-Rad, Hercules, CA). Puri-
ﬁed proteins were analyzed by SDS-PAGE and appeared as two
major bands with approximate sizes of 28 kDa and 32 kDa, respec-
tively. Puriﬁed GST-N-NS1 and GST-C-VP2 proteins (500 ug/animal)
were emulsiﬁed with TiterMax® Gold adjuvant (TiterMax® USA,
Norcross, GA) and then used to immunize animals as previously de-
scribed (Sun et al., 2009). All animal procedures were approved by
the KUMC Institutional Animal Care and Use Committee.
SDS-PAGE and Western blot analysis
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) was performed as previously described (Chen et al., 2010c). For
Western blotting, cell lysates were prepared 48 h post-transfection
and analyzed as previously described (Qiu et al., 2000, 2007b).
Lentivirus production and transduction
Lentiviruses were generated and concentrated following the instruc-
tions provided by Addgene (Cambridge, MA). Cells were transduced at a
multiplicity of infection (MOI) of ~10 as previously described (Chen et
al., 2010b, 2011).Flow cytometry analysis
Lentivirus-transduced CD34+ HSCs were collected 48 h post-
transduction. The cells were ﬁxed with 1% paraformaldehyde-
phosphate buffered saline (PBS) at room temperature for 30 min and
then permeabilized in 2% FCS-PBS containing 0.3% Tween-20 (PBST)
for 20 min. The cells were then stained with a 1:100-diluted anti-
Flag antibody (Agilent, Santa Clara, CA) for 45 min followed by stain-
ingwith a Cy5-conjugated anti-mouse antibody for 30 min. After incu-
bation, the cells were washed and incubated with 2 μg/ml 4′-6-
Diamidino-2-phenylindole (DAPI) in PBST for 30 min at 37 °C, and
then analyzed on a three-laser ﬂow cytometry (LSR II, BD Biosciences,
San Jose, CA) within 1 h. Flow cytometry data were analyzed using
FACS DIVA software (BD Biosciences).
Phospholipase A2-like activity assessment
Concentrations of the puriﬁed GST, GST-1M-, 52M-, and 101M-
VP1u proteins as well as GST-B19V-VP1u protein were determined
by using the CB-X assay kit (GBioscience, Maryland Heights, MO).
The proteins were aliquoted and stored at −80 °C. PLA2-like activity
was assayed following the protocol provided with the sPLA2 assay kit
(Cayman, AnnArbor, MI). The input of GST-fused proteinswas adjusted
to 0.2 nmol per well during analysis. A wavelength at 414 nmwas used
to detect the absorbance.
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